Pfizer (PFE) Gross Margin (2016 - 2025)
Historic Gross Margin for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to 74.95%.
- Pfizer's Gross Margin rose 46800.0% to 74.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 103.65%, marking a year-over-year increase of 432200.0%. This contributed to the annual value of 71.94% for FY2024, which is 138500.0% up from last year.
- Pfizer's Gross Margin amounted to 74.95% in Q3 2025, which was up 46800.0% from 74.22% recorded in Q2 2025.
- In the past 5 years, Pfizer's Gross Margin ranged from a high of 79.26% in Q1 2025 and a low of 120.24% during Q4 2023
- For the 5-year period, Pfizer's Gross Margin averaged around 45.68%, with its median value being 69.55% (2022).
- As far as peak fluctuations go, Pfizer's Gross Margin crashed by -958000bps in 2023, and later surged by 1120000bps in 2024.
- Pfizer's Gross Margin (Quarter) stood at 58.68% in 2021, then rose by 25bps to 73.22% in 2022, then crashed by -264bps to 120.24% in 2023, then soared by 158bps to 70.27% in 2024, then rose by 7bps to 74.95% in 2025.
- Its Gross Margin was 74.95% in Q3 2025, compared to 74.22% in Q2 2025 and 79.26% in Q1 2025.